Regeneron Pharmaceuticals Q2 2024 Adj EPS $11.56 Beats $10.61 Estimate, Sales $3.55B Beat $3.38B Estimate
Portfolio Pulse from Benzinga Newsdesk
Regeneron Pharmaceuticals (NASDAQ:REGN) reported Q2 2024 earnings per share of $11.56, beating the analyst estimate of $10.61. The company also reported sales of $3.55 billion, surpassing the $3.38 billion estimate and marking a 12.32% increase from the same period last year.
August 01, 2024 | 10:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regeneron Pharmaceuticals reported strong Q2 2024 results, with EPS and sales both beating analyst estimates. Sales increased by 12.32% year-over-year.
The strong earnings and sales performance, both exceeding analyst expectations, are likely to positively impact Regeneron's stock price in the short term. The significant year-over-year sales growth further supports a positive outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100